The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Mattel introduces a new Barbie doll representing Type 1 diabetes, complete with an insulin pump and glucose monitor, marking ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...